Lead generation and lead optimisation approaches in the discovery of selective, non-peptide ORL-1 receptor agonists and antagonists

Expert Opinion on Therapeutic Patents

Volumn 11, Issue 4, 2001, Pages 525-546

  Ronzoni, S ^a   Peretto, I ^a   Giardina, G A M ^a  

^a SmithKline Beecham SpA   (Italy)

Author keywords

Anxiety; Arylpiperidines; Benzimidazopiperidines; Cough; Diaminoquinolines; Morphinan hydroxamic acids; N OFQ; Nociceptin; Opioid receptor like 1; Orphanin FQ; Pain; Spiropiperidines

Indexed keywords

1 (1 CYCLOOCTYLMETHYL 3 HYDROXYMETHYL 4 PIPERIDYL) 3 ETHYL 1,3 DIHYDRO 2H BENZIMIDAZOL 2 ONE; 4 ARYL PIPERIDINE; 4 PHENYLPIPERIDINE DERIVATIVE; 4,6 DIAMINO QUINOLINE; 8 (2,3,3A,4,5,6 HEXAHYDRO 1H PHENALEN 1 YL) 1 PHENYL 1,3,8 TRIAZASPIRO[4.5]DECAN 4 ONE; [8 (1 NAPHTHYLMETHYL) 4 OXO 1 PHENYL 1,3,8 TRIAZASPIRO[4.5]DEC 3 YL]ACETIC ACID METHYL ESTER; ALPRAZOLAM; ANXIOLYTIC AGENT; BENZIMIDAZOPIPERIDINE; BENZODIAZEPINE DERIVATIVE; DIAZEPAM; ENADOLINE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; HYDROXAMIC ACID DERIVATIVE; LIGAND; LOFENTANIL; MITOGEN ACTIVATED PROTEIN KINASE; N (4 AMINO 2 METHYL 6 QUINOLINYL) 2 (4 ETHYLPHENOXYMETHYL)BENZAMIDE; NALOXONE BENZOYLHYDRAZONE; NOCICEPTIN; OPIATE AGONIST; OPIATE ANTAGONIST; OPIATE RECEPTOR; PIPERIDINE DERIVATIVE; PYRROLE DERIVATIVE; QUINOLINE DERIVATIVE; SPIRO (PIPERIDINE 4,1' PYRROLO[3,4 C]PYRROLE); SPIROPIPERIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ANXIETY; CHEMISTRY; DRUG ANALYSIS; DRUG POTENCY; DRUG RESEARCH; DRUG SELECTIVITY; DRUG STRUCTURE; FEEDING; LEARNING; MEDICAL DOCUMENTATION; MEMORY; MODULATION; MOUSE; NONHUMAN; PATENT; PATHOPHYSIOLOGY; PHARMACOLOGY; RAT; REVIEW; STROKE;

EID: 0035057560     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.11.4.525     Document Type: Review

References (84)

1. The orphan opioid receptor and its endogenous ligand nociceptin/orphaninFQ
2. ORL1, a novel member of the opioid receptor family: Cloning, functional expression and localization
3. Nociceptin/orphaninFQ and the opioid receptor-like ORL1 receptor
4. cDNA cloning of an orphan opiate receptor gene family member and its splice variants
5. cDNA cloning and regional distribution of a novel member of the opioid receptor family
6. Molecular cloning, tissue distribution and chromosomal localization of a novel member of the opioid receptor gene family
7. The potential therapeutic value of nociceptin receptor agonists and antagonists
8. The opioid-receptor-like-1 (ORL-1) as a potential target for new analgesics
9. Orphanin FQ: A neuropeptide that activates an opioid-like G protein-coupled receptor
10. Isolation and structure of the endogenous agonist of the opioid receptor-like ORL1 receptor
11. Nociceptin activation of the human ORL1 receptor expressed in Chinese hamster ovary cells: Functional homology with opioid receptors
12. Cellular actions of nociceptin: Transduction mechanism
13. Nociceptin receptor coupling to a potassium conductance in rat locus coeruleus neurons in vitro
14. + conductance by orphaninFQ/nociceptin in vasopressin-containing neurons
15. Modulation of voltage-gated calcium channels by orphanin FQ in freshly dissociated hippocampal neurons
16. 2+ in the SH-SY5Y human neuroblastoma cell line
17. + evoked glutamate release from rat cerebral cortex
18. 3H]-5-HT release from rat cerebral cortex slices
19. Modification of acetylcholine release by nociceptin in conscious rat striatum
20. Intracerebroventricular orphanin-FQ/nociceptin suppresses dopamine release in the nucleus accumbens of anaesthetized rats
21. Modulation of enkephalin release by nociceptin (orphaninFQ)
22. Nociceptin inhibits noradrenaline release in the mouse brain cortex via presynaptic ORL1 receptors
23. Orphanin FQ stimulates prolactin and growth hormone release in male and female rats
24. Depression of glutamatergic transmission by nociceptin in the neonatal rat hemisected spinal cord preparation in vitro
25. Inhibition of tachykinin release from peripheral nerve endings of sensory nerves by nociceptin, a novel opioid peptide
26. Actions of the ORL-1 receptor ligand nociceptin on membrane properties of rat periaqueductal gray neurons in vitro
27. Characterisation of the response in the rat vas deferens to the ORL1 agonist nociceptin
28. Nociceptin/orphanin FQ activates mitogen-activated protein kinase in Chinese hamster ovary cells expressing opioid receptor-like receptor
29. OrphaninFQ/nociceptin: A role in pain and analgesia, but so much more
30. OrphaninFQ is a functional anti-opioid peptide
31. Functional antagonism of μ-, δ-, κ-opioid antinociception by OrphaninFQ
32. Antinociceptive and morphine modulatory actions of spinal orphanin FQ
33. Bidirectional modulatory effect of orphanin FQ on morphine-induced analgesia: Antagonism in brain and potentiation in spinal cord of the rat
34. Identification and characterization of an endogenous ligand for opioid receptor homologue ROR-C: Its involvement in allodynic response to innocuous stimulus
35. Pharmacological characterization of orphaninFQ/nociceptin and its fragments
36. The novel neuropeptide orphanin FQ fails to produce conditioned place preference or aversion
37. Rats rapidly develop tolerance to the locomotor-inhibiting effects of the novel neuropeptide orphanin FQ
38. Nociceptin/orphaninFQ (N/OFQ) induces a quasimorphine abstinence syndrome in the rat
39. Enhanced spinal nociceptin receptor expression develops morphine tolerance and dependence
40. Nociceptin/orphaninFQ and drugs of abuse
41. Nociceptin/orphanin FQ microinjected into hippocampus impairs spatial learning in rats
42. Role of nociceptin systems in learning and memory
43. Facilitation of long-term potentiation and memory in mice lacking nociceptin receptors
44. OrphaninFQ, agonist of orphan opiod receptor ORL1, stimulates feeding in rats
45. Nociceptin stimulates locomotion and exploratory behaviour in mice
46. Changes in head dipping behaviour in the hole-board test reflect the anxiogenic and/or anxiolytic state in mice
47. OrphaninFQ acts as an anxiolytic to attenuate behavioral responses to stress
48. OrphaninFQ, a novel neuropeptide with anti-stress-like activity
49. Diuretic and antinatriuretic responses produced by the endogenous opioid-like peptide, nociceptin (orphaninFQ)
50. Nociceptin, an endogenous ligand for the ORL1 receptor, has novel hypotensive activity in rat
51. Studies of the cardiovascular effects of nociceptin and related peptides
52. The mouse vas deferens: A pharmacological preparation sensitive to nociceptin
53. Orphanin FQ: Receptor binding and analog structure activity relationships in rat brain
54. Structure - Activity relationship studies on the novel neuropeptide Orphanin FQ
55. Sensitivity of opioid receptor-like receptor ORL-1 for chemical modification of nociceptin, a naturally occurring nociceptive peptide
56. Structures that delineate Orphanin FQ and Dynorphin A pharmacological selectivity
57. Address and message sequences for the nociceptin receptor: A structure-activity study of nociceptin-(1-13)-peptide amide
58. Recognition and activation of the opioid receptor-like ORL1 receptor by nociceptin, nociceptin analogs and opioids
59. Structure-activity studies on nociceptin/orphaninFQ: From full agonist, to partial agonist, to pure antagonist
60. Pharmacology of nociceptin and its receptor: A novel therapeutic target
61. 2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist
62. Nociceptin/orphaninFQ receptor ligands
63. Comparison of the structure-activity relationships of nociceptin and dynorphin A using chimeric peptides
64. Structure-activity relationships of nociceptin and related peptides: Comparison with dynorphin A
65. 2, a new selective nociceptin receptor antagonist
66. Pharmacological characterization of the nociceptin receptor mediated hyperphagia: Identification of a selective antagonist
67. 3H-naloxone benzoylhydrazone: A reversible κ and slowly dissociable μ opiate
68. Characterization of the actions of naloxone benzoylhydrazone at μ-opioid, κ-opioid and ORL1 receptors in isolated tissues from rat and guinea-pig
69. Loss of antinociception induced by naloxone benzoylhydrazone in nociceptin receptor-knockout mice
70. Studies on the coupling of recombinant ORL-1 receptors to adenylyl cyclase
71. High-affinity, non-peptide agonists for the ORL1 (orphanin FQ/nociceptin) receptor
72. Comparative binding of μ and δ selective ligands in whole brain and pons/medulla homogenates from rat: Affinity profiles of fentanyl derivatives
73. 280 by His in TM6 of the human ORL1 receptor increases affinity but reduces intrinsic activity of opioids
74. Different domains of the ORL1 and κ-opioid receptors are involved in recognition of nociceptin and dynorphin A
75. Opioid activity profiles indicate similarities between the nociceptin/orphanin FQ and opioid receptors
76. 8-Acenaphthen-1-yl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as orphanin FQ receptor agonists
77. ORL1 receptor ligands: Structure-activity relationships of 8-cycloalkyl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-ones
78. A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: Anxiolytic profile in the rat
79. (8 -Naphthalen-1 -ylmethyl-4-oxo-1 -phenyl-1,3,8 -triaza-spiro[4.5] -dec-3-yl) -acetic acid methyl ester (NNC 63-0532) is a novel potent nociceptin receptor agonist
80. Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl -3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one (J-113397)
81. A potent and highly selective nonpeptidyl nociceptin/orphanin FQ receptor (ORL1) antagonist: J-113397
82. In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist
83. Pharmacological characterization of J-113397, a potent ORL1 receptor antagonist
84. 4-Aminoquinolines: Novel nociceptin antagonists with analgesic activity